Ascentage Pharma
Ascentage Pharma has 1 licensing announcement in this dataset, dated 2024-06-14.
- Country / operating region
- China
- Ticker
- 查無
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.ascentage.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| olverembatinib (HQP1351) | 查無 | 查無 | 查無 | 2024-06-14 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| olverembatinib (HQP1351) | 查無 | — | 查無 | 查無 | 查無 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2024-06-14 | Takeda | olverembatinib (HQP1351) | 查無 | 查無 | 查無 | 查無 | Option payment USD 100m Combined option exercise + milestones ≈ ≤ USD 1200m Exclusive option to enter a license; option exercise and milestone payments are conditional. |
| Counterparty | Territory | Royalties |
|---|---|---|
| Takeda | Worldwide excluding, among others, mainland China, Hong Kong, Macau and Taiwan | Double-digit royalties on annual net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無